BR9912356A - Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato - Google Patents

Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato

Info

Publication number
BR9912356A
BR9912356A BR9912356-8A BR9912356A BR9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A
Authority
BR
Brazil
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
administration
pharmaceutical composition
Prior art date
Application number
BR9912356-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw Burxynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw Burxynski filed Critical Stanislaw Burxynski
Publication of BR9912356A publication Critical patent/BR9912356A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
BR9912356-8A 1998-07-23 1999-07-02 Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato BR9912356A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
BR9912356A true BR9912356A (pt) 2001-04-17

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912356-8A BR9912356A (pt) 1998-07-23 1999-07-02 Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato

Country Status (20)

Country Link
US (2) US6258849B1 (2)
EP (1) EP1098643B1 (2)
JP (2) JP2002521329A (2)
KR (4) KR100399658B1 (2)
CN (3) CN100400039C (2)
AT (1) ATE257378T1 (2)
AU (1) AU759278B2 (2)
BR (1) BR9912356A (2)
CA (1) CA2336945C (2)
DE (1) DE69914084T2 (2)
DK (1) DK1098643T3 (2)
EA (1) EA004179B1 (2)
ES (1) ES2214866T3 (2)
ID (1) ID28160A (2)
IL (1) IL140848A (2)
NZ (1) NZ509244A (2)
PL (1) PL213698B1 (2)
PT (1) PT1098643E (2)
WO (1) WO2000004894A2 (2)
ZA (1) ZA200100622B (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
EP4731793A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
EP1098643B1 (en) 2004-01-07
KR100417101B1 (ko) 2004-02-05
DE69914084D1 (de) 2004-02-12
WO2000004894A3 (en) 2000-04-27
ES2214866T3 (es) 2004-09-16
US6943192B2 (en) 2005-09-13
KR20030027088A (ko) 2003-04-03
CN1605334A (zh) 2005-04-13
CA2336945A1 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
ZA200100622B (en) 2002-06-26
AU4854299A (en) 2000-02-14
PT1098643E (pt) 2004-05-31
AU759278B2 (en) 2003-04-10
NZ509244A (en) 2004-02-27
EP1098643A2 (en) 2001-05-16
EA200100168A1 (ru) 2001-08-27
KR20030027087A (ko) 2003-04-03
DE69914084T2 (de) 2004-10-28
KR100414587B1 (ko) 2004-01-13
JP2011051993A (ja) 2011-03-17
DK1098643T3 (da) 2004-05-24
WO2000004894A2 (en) 2000-02-03
HK1037142A1 (en) 2002-02-01
CN1191064C (zh) 2005-03-02
PL213698B1 (pl) 2013-04-30
US20010044466A1 (en) 2001-11-22
KR100417100B1 (ko) 2004-02-05
ATE257378T1 (de) 2004-01-15
IL140848A (en) 2005-05-17
ID28160A (id) 2001-05-10
PL345959A1 (en) 2002-01-14
CA2336945C (en) 2008-11-18
CN1319010A (zh) 2001-10-24
CN100400039C (zh) 2008-07-09
US6258849B1 (en) 2001-07-10
EA004179B1 (ru) 2004-02-26
KR20030027089A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
BR9912356A (pt) Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR9812588A (pt) Métodos e composições farmacêuticas para liberação oral de iodo molecular
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
KR960704543A (ko) 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease)
AR033688A1 (es) Composicion parenteral reconstituible
EA200501105A1 (ru) Фармацевтическая композиция
IL192287A0 (en) Pharmaceutical compositions and methods for use
KR970025615A (ko) 암 전이 억제제
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9912609A (pt) Métodos de uso de um análogo de somatostatina
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
KR830009776A (ko) 세포 보호 유도방법
IT8920465A0 (it) Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 13.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.